8-K: Cannabist Co Sells Virginia Assets for $130M, Exits Curaleaf Deal

The Cannabist Company Holdings Inc. has agreed to sell its Virginia cannabis assets to Parma Holdco LLC for $130 million, terminating a prior agreement with Curaleaf.

Summary

• The Cannabist Company Holdings Inc. (formerly Columbia Care) has entered into an Equity Purchase Agreement to sell all equity interests of its subsidiary, Green Leaf Medical of Virginia, LLC, to Parma Holdco LLC.
• The total consideration for the sale is $130 million, comprising $117.5 million in cash at closing and a $12.5 million Offset Escrow Amount.
• The Offset Escrow Amount will be released in parts: up to $1 million after post-closing purchase price adjustment, and the remainder (less indemnification obligations) nine months post-closing.
• Buyer will deposit a $23.7 million Deposit Escrow Amount within two business days of signing, which is released to the Company at closing or upon termination due to Buyer's material breach, or to Buyer for other reasons.
• The transaction is subject to regulatory approvals, including the Virginia Transaction Approval, and consent and lien releases from holders of the Company's 9.25% Senior Secured Notes and 9.0% Senior Secured Convertible Notes due December 31, 2028.
• Millstreet Credit Fund LP, a Noteholder, has consented to the transaction and will irrevocably and unconditionally guarantee Buyer's payment obligations.
• The Company terminated its previously announced Equity Purchase Agreement with Curaleaf, Inc., after determining Parma Holdco LLC's proposal was superior.
• A break-up fee of $3.3 million is payable to Curaleaf within two business days of the termination.

Sentiment

Score: 7

Explanation: The transaction provides a significant cash infusion and is deemed 'superior' to a previous offer, addressing 'operational and financial challenges'. The Millstreet guarantee adds payment certainty. However, the break-up fee and the underlying challenges indicate a company in a strategic restructuring phase rather than pure growth.

Positives

• Secured a 'superior' acquisition proposal for its Virginia assets, indicating better value than the previous Curaleaf agreement.
• The sale provides $130 million in total consideration, with $117.5 million in cash at closing, improving the Company's liquidity.
• Millstreet Credit Fund LP, a significant Noteholder, has consented to the transaction and will irrevocably and unconditionally guarantee Buyer's payment obligations, de-risking the transaction for The Cannabist Company.
• The transaction is part of a strategic review by a special committee, addressing 'ongoing operational and financial challenges' and aiming to optimize the Company's structure.
• A portion of the net proceeds is expected to be used to redeem Notes, which could reduce debt and interest expenses.

Negatives

• The Company is required to pay a $3.3 million break-up fee to Curaleaf, Inc. due to the termination of the prior agreement.
• The sale of assets indicates 'ongoing operational and financial challenges for the Company and the industry,' suggesting underlying business difficulties.
• A significant portion of the purchase price ($12.5 million Offset Escrow Amount) is subject to escrow and post-closing adjustments, with full release up to nine months after closing, potentially delaying full cash realization.

Risks

• The cannabis business, despite state-level legalization, remains illegal under U.S. federal law (Controlled Substances Act), exposing parties to potential civil forfeiture of assets and criminal penalties.
• All representations and warranties regarding compliance with law are explicitly qualified by the fundamental non-compliance with Federal Cannabis Laws, meaning no claims can be brought related to 'Excluded Federal Claims' (federal marijuana laws).
• The transaction is subject to various closing conditions, including regulatory approvals (Virginia Transaction Approval) and lien releases from Noteholders, which could delay or prevent closing.
• The Company faces 'ongoing operational and financial challenges' within the broader cannabis industry, which could persist even after this asset sale.
• The purchase price is subject to post-closing adjustments based on cash, debt, net working capital, unpaid transaction expenses, and certain transaction payments, which could reduce the final consideration received.

Future Outlook

The Company expects the transaction to close early in 2026 or before, subject to regulatory approvals. A portion of the net proceeds from the sale is anticipated to be used for the redemption of the Company's Senior Secured Notes. The Company's Board of Directors, through a special committee, continues to review strategic alternatives to address ongoing operational and financial challenges.

Management Comments

• The Board of Directors of the Company formed a special committee of independent directors to review strategic alternatives.
• The special committee, with support from external financial and legal advisors, is considering a range of options, including potential asset sales, mergers, or other strategic, financial or restructuring transactions or proceedings.
• The review is being conducted in consideration of the ongoing operational and financial challenges for the Company and the industry.
• The Transaction forms part of this strategic review.

Industry Context

The transaction occurs within a U.S. cannabis industry characterized by significant state-level legalization but persistent federal prohibition, leading to operational and financial challenges for multi-state operators like The Cannabist Company. The sale of a key state-level asset, coupled with a strategic review, suggests a broader trend of companies divesting non-core or underperforming assets to improve financial health and focus on more profitable markets amidst a complex regulatory and capital environment. The involvement of a credit fund (Millstreet) as both a Noteholder and a guarantor for the buyer highlights the role of debt financing and restructuring in the industry.

Comparison to Industry Standards

• The sale of Virginia assets for $130 million, including 5 active retail locations, 1 in development, and 82,000 sq ft of cultivation/production, can be benchmarked against other recent cannabis M&A transactions in limited-license states. For example, similar transactions in states like Pennsylvania or Ohio have seen valuations vary widely based on market maturity, license scarcity, and operational profitability.
• The termination of the Curaleaf agreement for a 'superior' offer suggests competitive M&A activity in the sector, where companies are actively seeking better terms or strategic fits, even if it incurs break-up fees. Curaleaf itself has been active in M&A, and this indicates The Cannabist Company was able to leverage the go-shop period effectively.
• The explicit disclosure of federal cannabis illegality and associated risks (civil forfeiture, criminal penalties) is standard practice in SEC filings for U.S. cannabis operators, reflecting the unique regulatory environment compared to other industries.

Corporate Governance

Legal Proceedings

• The filing explicitly states that no Proceeding may be brought by any Party arising in connection with an 'Excluded Federal Claim,' which refers to any claim or demand related to U.S. federal laws concerning marijuana, due to the inherent conflict between state and federal cannabis laws.

Related Party Transactions

• Millstreet Credit Fund LP, a Noteholder, is a party to the Equity Purchase Agreement, consenting to the transaction and guaranteeing Buyer's payment obligations. Millstreet indirectly owns or controls $50,000,000.00 of the Company's Notes.

Stakeholder Impact

• **Shareholders**: The sale provides liquidity and is part of a strategic review to address financial challenges, potentially stabilizing the Company's financial position. The 'superior' offer suggests a better return on the Virginia assets. However, the sale of assets reduces the Company's operational footprint.
• **Noteholders**: The transaction requires consent from Noteholders, and a portion of the proceeds is expected to be used to redeem Notes, which could benefit Noteholders by reducing exposure or improving credit quality. Millstreet's guarantee further secures their interests.
• **Employees (Virginia)**: Employees of Green Leaf Medical of Virginia, LLC will be offered employment by the Buyer, leading to a change in employer. The Company is responsible for all pre-closing employee obligations and severance for Transferred Employees.
• **Curaleaf, Inc.**: Will receive a $3.3 million break-up fee, compensating for the termination of their prior agreement.

Next Steps

• Buyer to deposit $23.7 million Deposit Escrow Amount within two business days of signing.
• Company to pay Curaleaf a $3.3 million break-up fee within two business days of termination.
• Obtain Virginia regulatory approvals for the transaction and transfer of Marijuana Permits.
• Obtain consent and lien releases from Noteholders.
• Close the transaction, expected early in 2026 or before.
• Buyer to deliver a revised balance sheet and Closing Statement within 60 calendar days after the Closing Date for post-closing adjustments.
• Cannabist to engage an auditor selected by Buyer for a fiscal year 2025 audit within five business days of the agreement date.
• A portion of the net proceeds from the transaction is expected to be used to redeem Notes.
• The special committee continues to review other strategic alternatives for the Company.

Key Dates

Recommendation

The sale of Virginia assets for $130 million, deemed a 'superior' offer, provides much-needed liquidity for The Cannabist Company, which is undergoing a strategic review due to 'operational and financial challenges.' The Millstreet guarantee on the buyer's payment significantly de-risks the transaction. While the $3.3 million break-up fee to Curaleaf is a cost, the overall cash infusion and potential debt reduction are positive. However, the underlying 'operational and financial challenges' and the inherent federal illegality risks of the cannabis industry remain. This transaction is a step towards stabilization and strategic refocus rather than a clear growth catalyst, warranting a 'hold' as the Company navigates its broader restructuring and the complex regulatory landscape.

Keywords

Cannabis, Marijuana, Asset Sale, Merger & Acquisition, SEC Filing, 8-K, Virginia, Green Leaf Medical, Parma Holdco, Millstreet Credit Fund, Curaleaf, Strategic Alternatives, Regulatory Approval, Debt Redemption, Controlled Substances Act